or
Remember me
Back
Kneat (KSI TSX)
The Business: Kneat (KSI) is a hidden gem in the Canadian tech sector that digitizes validation for the life sciences industry. It replaces the roomfuls of paper binders and wet-ink signatures required by the FDA with a secure cloud platform. Essentially, it is the digital compliance backbone for pharmaceutical and biotech giants. Their customer list includes most of the top 20 global pharmaceutical companies.
The Strategy: The company executes a textbook “Land and Expand” strategy. They don’t sell to an entire global conglomerate at once; they win a contract for a single facility. Once the software proves its efficiency, it rolls out to the client’s 50 to 100 other sites globally. This creates a massive competitive moat—once a pharma company digitizes its compliance data on Kneat, switching away is logistically painful and risky.
Valuation: This “quiet compounder”, revenue growth has slowed a bit in 2025 to 30 per cent from 40 per cent in previous years but the prospects are still bright.
The valuation has come down to five to six times the enterprise value-to-revenue. We think this is a very attractive entry point.
